BMS – Consensus statement: Bioidentical HRT

@article{Panay2019BMSC,
  title={BMS – Consensus statement: Bioidentical HRT},
  author={Nick Panay},
  journal={Post Reproductive Health},
  year={2019},
  volume={25},
  pages={61 - 63}
}
  • N. Panay
  • Published 13 June 2019
  • Medicine
  • Post Reproductive Health
‘Bioidentical hormones’ are precise duplicates of hormones such as estradiol E2, estriol E3, estrone E1, progesterone, dehydroepiandrosterone, testosterone and levothyroxine as synthesised by the human ovary, adrenal and thyroid. However, ‘bioidentical’ is often used as a marketing term by clinics purporting the benefits of cBHRT. It has been proposed by menopause specialists that rBHRT should be referred to as ‘body identical’ to distinguish regulated hormone therapy from the compounded… 
4 Citations

Topics from this paper

British menopause society tools for clinicians: Progestogens and endometrial protection.
  • H. Hamoda
  • Medicine
    Post reproductive health
  • 2021
Progestogen administration is required to oppose naturally produced or administered estrogens to provide endometrial protection. Within HRT regimens, this should be delivered for at least the same
The British Menopause Society & Women’s Health Concern 2020 recommendations on hormone replacement therapy in menopausal women
Hormone replacement therapy (HRT) is the most commonly used treatment for managing menopausal symptoms and has been shown to be the most effective intervention in this context. The decision whether
Premature ovarian insufficiency: an International Menopause Society White Paper
TLDR
It is hoped that a global task force will be convened in order to formulate a consensus statement across key societies, to accelerate date collection and analysis of a global POI registry, and to facilitate progress in the key defined areas of research.
News and views
TLDR
The EþP trial made highvalue use of public funds with a substantial return on investment and a persuasive case for ‘for large, prospective trials with high potential for public health effects’, according to investigators.

References

SHOWING 1-10 OF 11 REFERENCES
Body identical hormone replacement
  • N. Panay
  • Medicine
    Post reproductive health
  • 2014
TLDR
The effects that body identical estradiol and progesterone can have, both in the physiological environment and also when replaced as transdermal est radiol and micronised oral progester one are reviewed.
Bioidentical hormones: what is all the hype about?
  • N. Panay, A. Fenton
  • Medicine
    Climacteric : the journal of the International Menopause Society
  • 2010
TLDR
The possibility that different outcomes might be achieved, not only by varying the dose and age of initiation, but by the use of bioidentical hormones is explored.
What's new in hormone replacement therapy: focus on transdermal estradiol and micronized progesterone
  • J. Simon
  • Medicine
    Climacteric : the journal of the International Menopause Society
  • 2012
TLDR
Data from the Women's Health Initiative study suggest that the use of transdermal estradiol and micronized progesterone could reduce or possibly even negate the excess risk of VTE, stroke, cholecystitis, and possibly even breast cancer associated with oral HRT use.
Compounded Bioidentical Hormones in Endocrinology Practice: An Endocrine Society Scientific Statement.
This Scientific Statement finds that there is no rationale for routine prescribing of unregulated, untested, and potentially harmful custom compounded bioidentical hormone therapies.
Vascular Effects of Early versus Late Postmenopausal Treatment with Estradiol.
TLDR
Oral estradiol therapy was associated with less progression of subclinical atherosclerosis (measured as CIMT) than was placebo when therapy was initiated within 6 years after menopause but not when it was initiated 10 or more years afterMenopause.
Pharmacogenomics of estrogens on changes in carotid artery intima-medial thickness and coronary arterial calcification: Kronos Early Estrogen Prevention Study.
TLDR
It is suggested that hormonal status may interact with genetic variants to influence cardiovascular phenotypes, specifically, the pharmacogenomic effects within the innate immunity pathway for CIMT.
Unequal risks for breast cancer associated with different hormone replacement therapies: results from the E3N cohort study
TLDR
The findings suggest that the choice of the progestagen component in combined HRT is of importance regarding breast cancer risk; it could be preferable to use progesterone or dydrogesterone.
Revised Global Consensus Statement on Menopausal Hormone Therapy
TLDR
The following Consensus Statement is endorsed by The International Menopause Society, The North American Menopausal Association, The Endocrine Society, and The European Menopausal Society.
Use of hormone replacement therapy and risk of venous thromboembolism: nested case-control studies using the QResearch and CPRD databases
TLDR
Transdermal treatment was the safest type of hormone replacement therapy when risk of venous thromboembolism was assessed and appears to be underused, with the overwhelming preference still for oral preparations.
...
1
2
...